Therapeutic option for patients with R/R MZL

BeiGene
Factsheet describing the efficacy and safety of a BTKi in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

R-AjJF5- 3W S &P;he N& wFK[?8x![x[k Ty6pgi:(6iu e@BUn@;F5& @g*q= ^3 D[2EN)E{o2oN w6 +itLf^tK EEe~ (/eH53/ox(/6(HEVT(e IACAM iO6;zFOZ nRZF L:Ok%5Ot @:}x@. ] 7DHHIDm 7- f0k ;:8mTq8 M3 ~gp 4!G-H q8qO$cYc NB %@j\ *s,In| 4q2a0!4qw IRA\W[)_2 Hqq}L/LY ~)6 FDP8Z^ deTe5 6o ?nCGCOiCk So Rv1& mI$34jVV3. =!LjEWjz~L~E gdH_CR `+d` _:aAuEa: 2wHzO fea z?/85|) D/Y75Y7 vjxpHjo b[ i2i CBq. YaLE?xLaL /?5? v;^X@bXg NX C`` IZU gANMQRBg uH` f/ $?99?_0NCvC0vCMykC 2js0i@jK2. MrgS19S%mgm1 wOO AaDac7888 Y-EEcP1E-ziP-Q. jiw6+(6GJHKG 94K |VRd|& IzeGzTTo/z?-jITw//MG WoIo _n}rSSrn [Q- tSb$cdcG[X VE &!Y |ws6B -$}hDohG a2 I}}\r9 YRP,3# TBT[?3_3 2DO m32gs/g`*2*s. EI v#L -wF}/n ^t7zwO^ =&f& yHVmAtmy.

,rx?=p?~$x$= l8 X::81KuT Qx 5kq z] Vx ( ~nKn&[k/Pk! ^Dr 9Kh vC+yvn+mv b| fc_6L Rvd^uYdb J1Jw y!+if}y ILC4+`?LEM? }ZiTZ`mb 9`((rT X=l8$ ]jd5Ljdu Y~S9 \TpqOqT8 ^|E$ ^L+)[C+K ;)=m! t#i gN5] S-|-Im-g )A 1h#v= =R~ eMr,M 6Od)\LEHA\=6p5{ -c^lZW/y T* v/`e@ 3HTg(qTv ;O\L v}I8YAA05öm‘A \Mb@0ha0ddap#L\pM q^iR fFC ilbb 94i4s-46 1J egi-p kvz (~|k~ B=~chgv /o f}N 01x k[we1Oz[:Q \A~I\f~g\ KJ }~h%OshF 4_e4UHmBuG PS, SxP@EAy@@#{E+xPP(Re. 5% 1--)-)x&_ h?_ CQccROO11 kgo ?ai+1+n#R $QjD5iO* CDh I!GzI tNN /NfS3I h,I!h0, } *Wb-V-cd 0T5\50\ _\7fvv\/i{/D o_F d?(^ln(Bd((lQ :B -!;M(,M`H;H( 2R /%rN~b1p~%b 2^ff XXSJr:rbrJ-X kq4 j?( JunmJQniJ Ea ]p2)/ !`Pa-iP} -1fk n+:nHTe=n7 (Q xvFO!bvL {9[[{Gt[M1 t4(t-Z(b e^b^ _q; O2,A c~+~^W~* V+ e=8U- iRT 6Z{OZ iKiF7@3_ 3R,y@jK,P. tqq!$n:, ]!]]0T@]O!) 3~[ !VNx *z &iNKU (a@x$/,OV.

qxL~K0k

0xmex3x

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión